P-glycoprotein-mediated multidrug resistance has emerged as different laboratories. 8 Furthermore, there has been lack of one of the most attractive targets to improve anticancer theragreement on the optimal methodology for characterizing P- 
probes.
required to inhibit completely P-glycoprotein transport activity
Functional assays have traditionally been labor intensive is higher than generally recognized. Thus, the level of P-glycorequiring individual analysis of fresh specimens. In addition, 
butyl isonitrile)technetium(I) ([ 99m Tc]Sestamibi) as a functional
Keywords: multidrug resistance; MDR; P-glycoprotein probe of P-glycoprotein transport activity in a solid tumor model. 9 [ 99m Tc]Sestamibi is an organometallic, lipophilic cation which we have shown to be a multidrug resistant gene Introduction (MDR)1 P-glycoprotein transport substrate. [9] [10] [11] The high specific activity and low nonspecific binding of this radiopharmaThe characterization of cell lines resistant to multiple chemoceutical make it a sensitive probe of P-glycoprotein function therapeutic agents has led to the identification of several genin vivo permitting the characterization of its cellular accumuetic mechanisms of multidrug resistance.
1 P-glycoproteinlation through either biodistribution or scintigraphy. Analysis mediated transport, the most extensively studied mechanism, of multidrug-resistant cell lines with [ 99m Tc]Sestamibi has indihas proved to be an attractive target to improve cancer cated a high capacity, allosterically modulated translocation chemotherapy.
1-5 The P-glycoprotein appears to function as mechanism for P-glycoprotein transport. 11 an energy-dependent transport pump capable of decreasing In this report, we examine a variety of functional assays of the intracellular concentration of a wide range of anticancer P-glycoprotein transport activity. Comparisons between cytoagents. Preclinical investigations have demonstrated that Ptoxicity and fluorescent and radioactive probe accumulation glycoprotein transport activity can be pharmacologically in cell lines expressing different levels of P-glycoprotein are manipulated by a large number of compounds. 6 These agents utilized to define better the sensitivities of the assays and have been shown to inhibit P-glycoprotein transport, apparfurther our understanding of P-glycoprotein transport. ently by interfering with substrate binding. Cell survival assays purified as described and diluted in 90% ethanol, 10% 150 mM sodium chloride as 700 Ci/ml. Transport experiments were performed in siliconized microfuge tubes and Cell survival assays were performed in 96-well plates with alamarBlue (Alamar, Biosciences, Sacramento, CA, USA) as a initiated by addition of 732.5 l at 2-3 × 10 6 cells/ml to 10 l [ 99m Tc]Sestamibi solution and 7.5 l of vehicle alone or of measure of cell survival. AlamarBlue is a non-toxic, water soluble indicator dye which measures mitochondrial activity proreversal agent in vehicle at 100-fold the desired concentration. The tubes were incubated in a 37°C water bath with viding a quantitative assessment of cell survival. Mitochondrial activity reduces the compound which can be measured occasional mixing. The reaction was terminated by spinning 250 l aliquots from the reaction for 10 s through 800 l of colorimetrically. Cells were grown without cytotoxic agents for 3 days prior to initiating cell survival assays. Serial a 75:25 mixture of silicon oil, density = 1.050 (Aldrich, Milwaukee, WI, USA), and mineral oil, density = 0.875 (Acros). dilutions of vinblastine or doxorubicin were added to the wells in 50 l at four times the required concentration and An aliquot of the aqueous phase was obtained to normalize extracellular concentration of the tracer to cell-associated mixed with 50 l of media, cyclosporin A (CsA) (Sandoz Pharmaceuticals, East Hannover, NJ, USA), or SDZ PSC 833 (Psc) activity, then the oil and aqueous phases were aspirated and the cell pellet extracted in 0.5 ml of 1% SDS, 10 mM sodium (the gift of Sandoz Pharmaceuticals) at four times the desired concentration. Approximately 5000 cells were added to the borate. Radioactivity was determined on a gamma counter (Beckman Cobra, 130-165 keV window) and cell protein was wells in 100 l of media bringing the total volume to 200 l. Cells were incubated for four days at 37°C in a 5% CO 2 incudetermined by the BCA assay (Pierce, Rockford, IL, USA). bator. The AlamarBlue (20 l) was then added to each well for 24 h and the absorbance at 550 nm and 595 nm was determined in a microplate reader (Biorad, Hercules, CA, at 37°C for 1 h or as otherwise indicated in the presence of rhodamine 123 or DiOC2. The effect of P-glycoprotein reveris the molar extinction co-efficient for oxidized AlamarBlue, 110 000 and 59 000 for 550 nm and 595 nm, respectively. sal agents on the accumulation of rhodamine 123 was characterized over a range of CsA and Psc concentrations. The conThe fraction of surviving cells was determined by directly comparing the amount of alamarBlue reduced by the expertents of two tubes, one with 500 l of the reversal agent and rhodamine 123, both at twice the final concentration, and a imentally treated cells to the amount reduced by cells which have not been treated with cytotoxic agents or reversal agents.
second tube with cells in 500 l were mixed on ice and then incubated at 37°C for 1 h. Quantification of fluorescence was done on a Becton Dickinson (Sparks, MD, USA) FACSCANII using LYSYS or CellQuest software applications.
Daunorubicin accumulation Western blot analysis
Cells were washed in phosphate-buffered saline and resuspended at a concentration of 2 × 10 6 cells/ml in RPMI supEnriched membrane preparations from drug-sensitive and drug-resistant cells were obtained by rinsing the cells in phosplemented with 10 mM Hepes, pH 7.3 and 1% fetal calf serum. Cells (100 l) were added to a microfuge tube containphate buffer saline and allowing them to swell in a solution of 0.25 M sucrose, 10 mM Hepes, pH 7.3 on ice for 10 min. ing 50 l of [ 3 H]daunorubicin, specific activity 4.6 Ci/mmol (Dupont NEN, Boston, MA, USA) diluted 1 to 500 in 4 M
The cells were sonicated on ice and nuclei and unbroken cells spun down at 600g for 9 min at 4°C. The supernatant was daunorubicin and 50 l of four times the desired concentration of reversal agent. The tubes were mixed yielding a final transferred to a new tube and spun at 100 000 g for 15 min at 4°C in a RC M120 ultracentrifuge (Sorvall, Bloomington, concentration of 1 M daunorubicin and 0.11 M [ 3 H]daunorubicin in the presence of the desired concentration of reversal DE, USA). The pellet was resuspended in 200 l of Dulbecco's PBS and frozen at −70°C for further use. Membrane prepagent. The tubes were incubated at 37°C for 1 h and the reaction terminated by spinning the reaction for 10 s through 250-arations were added to sample buffer with ␤-mercaptoethanol without heating, fractionated on 10% sodium dodecyl sulfate 500 l of a 80:20 mixture of DOW 550 silicon oil and light mineral oil (Sigma, St Louis, MO, USA) which had been laypolyacrylamide gels and transferred to nitrocellulose in a Hoeffer transfer apparatus using a solution comprised of ered on top of 5 l formic acid. The tubes were immediately placed on dry ice and allowed to freeze. The tips of the tubes 200 mM glycine, 25 mM Trizma base, and 20% methanol. The nitrocellulose was rinsed in 10 mM Trizma base pH 8.0, containing the cell pellet were cut off and placed in 5 ml of Biofluor (Dupont NEN). The samples were allowed to melt 150 mM sodium chloride, 0.05% Tween 20 (TBST) and the proteins then blocked in TBST with 5% Carnation instant milk and mixed thoroughly prior to determination of radioactivity (c.p.m.) in a scintillation counter on the tritium channel at room temperature for 30 min and then rinsed again in TBST. Monoclonal antibody C219 16 was diluted 1:150 in TBST and (Beckman, Columbia, MD, USA; model LS1801). incubated with the nitrocellulose filter at room temperature for 1 h and excess antibody was washed off in TBST. A 1:7500 dilution of anti-mouse immunoglobulin conjugated to alkaline phosphatase (Promega, Madison, WI, USA) was used to detect the primary antibody with NBT/BCIP substrate as recommended by the manufacturer (Promega).
Results
Characterization of P-glycoprotein expression P-glycoprotein expression was characterized by Western blot analysis of membrane fractions from the parental Cem and 8226/S and their respective multidrug-resistant derivatives, Cem/Vbl300 and 8226/Dox6. High levels of a 170 kDa protein are detected by monoclonal antibody C219 directed against P-glycoprotein in the Cem/Vbl300 cell line (Figure 1) . Significantly less is detected in the 8226/Dox6 cell line. The parental Cem and 8226/S cell lines have undetectable amounts of P-glycoprotein.
Cell survival assays
The Cem/Vbl300 cell line is a highly resistant cell line as depicted in Figure 2a . The vinblastine concentration which inhibits 50% survival (IC 50 ) of the resistant derivative is approximately one million-fold higher than the parental cell line. Increasing concentrations of the reversal agents CsA and the resistant cells to vinblastine. 17 The 8226/Dox6 cells are approximately 20-fold resistant to doxorubicin compared to the parental 8226/S cell line (Figure 2b ). Both CsA and Psc slightly more potent than CsA in these cells, however, it is sensitize the resistant cell line to doxorubicin. Psc appears difficult to ascertain directly since both reversal agents sensitize the resistant cell line to the level of the parental cell line by 1 M. The estimated concentrations of CsA and Psc required to sensitize resistant cell lines to 50% of the difference between the IC 50 of the sensitive and resistant cell lines are listed in Table 1 .
Accumulation of [ 3 H]daunorubicin
The differential accumulation of daunorubicin was characterized in the two pairs of cell lines and their multidrug- both CsA and Psc increased the accumulation of the radioactive substrate in both multidrug-resistant cell lines in a concentration-dependent fashion. There was a modest change in accumulation in the parental cell lines with the reversal agents. Psc was more potent in both resistant cell lines than CsA resulting in greater tracer enhancement at equimolar concentrations ( Figure 4 and Table 1 ). Inhibition of P-glycoprotein function with Psc resulted in higher maximal levels of accumulation than CsA. Equivalent inhibition of P-glycoprotein function occurred at lower concentrations with both CsA and Psc in the 8226/Dox6 cell line than in the Cem/Vbl300 cell line.
Accumulation of fluorescent probes
The differential accumulation between the sensitive and resistant cell lines was characterized over a range of probe concentrations ( Figure 5 ). Optimal concentrations for discriminating between the sensitive and resistant cell lines differed between the cell lines. Lower concentrations did not provide sufficient signal, while higher concentrations obscured the specific signal presumably due to nonspecific binding or saturation of Pglycoprotein transport activity. The kinetics of rhodamine 123 accumulation were characterized in the two pairs of cell lines ( Figure 6 ). Saturation in the sensitive cell lines was not reached by 60 min of incubation, while the resistant cell lines maintained a steady-state level of accumulation. The Cem cell Table 1 ). In the 8226/Dox6 cell line, lower concentrations of either reversal agent were required to increase fluorescence compared to the Cem/Vbl300 cell line ( Figure 7 and Table 1 ). High concentrations of either reversal agent had little effect on the accumulation of rhodamine in either the Cem or the 8226/S parental cell lines.
Discussion
We have evaluated and compared assays of P-glycoprotein function in two different multidrug-resistant cell lines. The Cem/Vbl300 cell line expresses much higher levels of P-glycoprotein than the 8226/Dox6 cell line. Several general points can be made from these observations. First, the highly drug resistant Cem/Vbl300 cell line permits greater discrimination of differences detected with reversal agents and P-glycoprotein functional probes. Second, cell lines expressing less P-glycoprotein required lower concentrations of reversal agents to inhibit P-glycoprotein function in both cytotoxicity and transport assays. Third, there is a wide range of differential accumulation of the transport probes between the sensitive and resistant cell lines. Fourth, the optimal concentrations for the fluorescent probes to characterize P-glycoprotein transport differ depending upon the level of P-glycoprotein expression. potent in increasing the accumulation of rhodamine Use of fluorescent probes is thus confounded by significant ant cell lines with prolonged incubation suggests that the binding is most likely intracellular in a compartment acted on differences in the optimal probe concentration required to detect various transport activities. This could present caliby P-glycoprotein. In addition, the persistently low accumulation in the resistant cell lines indicates that the P-glycobration problems when the level of P-glycoprotein expression is unknown in a given clinical sample. Finally, the reversal protein must function as a high capacity transporter. Note that even a small amount of nonspecific binding in the resistant agent Psc is more potent than CsA in potentiating cytotoxicity and substrate accumulation. 18 cell lines could dramatically decrease the differential accumulation in relation to sensitive cells. However, high levels of These observations have several significant consequences in evaluating hematologic malignancies for P-glycoprotein nonspecific binding confined to the sensitive cells would counter the above effect and might actually increase the differexpression. Differences in P-glycoprotein expression may affect the optimal concentration of the fluorescent probes to ential accumulation relative to the resistant cell lines. Previous evaluation of the adherent hamster V79 cell line measure transport activity. The differences in cellular accumulation of the probes between samples may therefore reflect not and its doxorubicin-selected derivatives 77A and LZ-8 cell lines with [ 99m Tc]Sestamibi similarly demonstrated the need only P-glycoprotein functional activity but also the concentration-dependent ability to detect these differences which are for higher concentrations of CsA, verapamil, and quinidine for complete inhibition of P-glycoprotein function. 9, 11 There are determined in turn by the level of P-glycoprotein. This is not found with [
99m Tc]Sestamibi because it is used at tracer levels several possibilities for this 'shift to the right' in concentration required to inhibit P-glycoprotein in the more highly resistant (picomolar) and may be an advantage for the use of this radioprobe. Accumulation differences between drug resistance and cell lines. It is not clear if this is simply due to the levels of P-glycoprotein expression. It is possible that the P-glycosensitive cells and the quantification of tracer enhancement by addition of reversal agents is independent of [ 99m Tc]Sestamibi protein in highly resistant cell lines has different functional properties due to post-translational modifications such as probe concentration for all ranges relevant for in vitro or in vivo assays. 11 In addition to differences between P-glycophosphorylation or glycosylation. Alternatively, it is possible that reversal agents interact with the P-glycoprotein differently protein expression in the samples themselves, it is important to consider which cell lines are to be used as controls for than transport substrates with slower on-off rates 18 and may be transported less efficiently than cytotoxic agents. 11, 20 Finally, standardizing the assay procedures. Similarly, since cells expressing different levels of P-glycoprotein require different differential distribution of substrates or reversal agents in subcellular compartments affecting delivery for transport could concentrations of specific reversal agents to inhibit a specific amount of transport activity, it becomes difficult to compare similarly be occurring in cells expressing varying levels of Pglycoprotein. Nevertheless, this phenomenon appears to be patient samples unless the absolute amount of P-glycoprotein is known, or a saturating concentration of a high potency probe independent. P-glycoprotein-mediated multidrug resistance remains one reversal agent is used. Assays to evaluate percent reversal with 10 M CsA, for example, will significantly underestimate of the most attractive targets to improve cancer chemotherapy. Characterization of P-glycoprotein function is a critical maximal reversal potential in cells expressing high levels of P-glycoprotein, while 10-30 M Psc will fully reverse all levcomponent in determining the effects of therapeutic regimens aimed at interfering with P-glycoprotein function. The obserels of expression. Similarly, we have here, and previously, demonstrated only partial reversal of [ 99m Tc]Sestamibi vations presented here indicate that careful calibration of Pglycoprotein detection systems is essential in making meanaccumulation with CsA, in contrast to verapamil and quinidine. 9, 11 Complete reversal is obtained, however, with the ingful comparisons between patient samples and demonstrate how the level of P-glycoprotein expression may confound more potent CsA analog, Psc. If the amount of reversal is used as one criteria for the functional level of P-glycoprotein, it may intersample comparisons. be important that this be assayed with a sensitive probe using a high potency reversal agent. Acknowledgements The differences in probe accumulation may in part be determined by the driving forces responsible for uptake of the We would like to thank Kyriaki Dunussi-Joannopoulos for probes. The lipophilic, cationic probes enter the cells in help in preparing the Figures. This work was supported in response to the electrochemical gradient across the plasma parts by grants from Sandoz Pharmaceuticals and the Danamembrane. The intracellular pools for the fluorescent probes Farber Cancer Institute (JMC) and the DOE (ER61885) (DPand radioactive cytotoxic agents are not entirely known. How-W). DP-W is an Established Investigator of the American ever, the mechanisms of net accumulation of [ 99m Tc]Sestamibi Heart Association. are generally well characterized. Unidirectional uptake is driven by the plasma membrane and mitochondrial membrane potentials 19 
